Thermo Fisher Scientific (NYSE:TMO) announced that it completed its acquisition of a Sanofi facility in New Jersey. The company acquired Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey. In July, the company announced its plans to acquire this site and continue producing a portfolio of Sanofi therapies there while opening the facility… The post Thermo Fisher completes acquisition of Sanofi’s fill-finish, packaging site in New Jersey appeared fir...| Pharmaceutical Processing World
Find out what Sanofi has been up to in 2025, especially as it just closed the Opella deal and is now expanding its pipeline. The post The Sanofi pipeline in 2025: Is the play-to-win strategy working? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is g...| Labiotech.eu
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development